Regression in the radial growth phase (RGP) of primary cutaneous melanomas is common and has been shown to be an adverse prognostic factor. However, the underlying mechanism is unclear. We performed dual immunohistochemical staining of podoplanin and S-100 on paraffin tissues from 321 patients with vertical growth phase primary melanomas, who had 10 years or more of follow-up. Lymphatic vessel density (LD) and lymphatic invasion (LI) were quantified and documented. The time to first metastasis and melanoma-specific death (MSD) from the date of definite treatment were analyzed using univariate and multivariate Cox models. Among the 116 vertical growth phase melanomas that had regression in the adjacent RGP, 75 (23%) were classified as complete and 41 (13%) were classified as partial. LD was significantly higher (P<0.001) in the 75 lesions with complete regression (mean±SD, 23.7±12.3/mm 2 ) compared with the 41 lesions with partial regression (15.5±7.1/mm 2 ) and was lower in 155 areas of the adjacent normal dermis (7.3±3.5/mm 2 ) and 69 areas of the distant normal dermis (5.5±2.6/mm 2 ). Patients whose lesions had areas of complete regression with LI and either high or low LD or had no LI with high LD, had shorter time to first metastasis (hazard ratio = 2.5, 3.8, and 2.5, respectively) and increased risk of melanoma-specific death (hazard ratio = 3.1, 1.3 and 3.0, respectively) than those with no LI, and low LD or those without areas of complete regression. These data indicate that complete RGP regression is associated with significantly increased LD. In addition, the adverse prognostic effect of RGP regression is at least partially mediated through lymphangiogenesis and LI in this area.
R adial growth phase (RGP) regression is defined histologically, and it is different from the disappearance/regression of clinically established pigmented lesions. Histologic regression can be seen in lesions without clinical evidence of disappearance or fading. RGP regression of primary melanomas [with or without an associated vertical growth phase (VGP)] has been defined as increased vascularity and delicate fibroplasia in the papillary dermis, a lymphocytic and melanophage infiltrate, and an absence of dermal melanoma cells. In complete regression, melanoma cells are absent in the overlying epidermis, whereas in partial regression they are present in the epidermis. 9 RGP regression is common, particularly in thin lesions. The incidence of regression in melanomas of all thicknesses has been estimated at about 10% to 35%, and up to 58% in melanomas with thicknesses of r0.75 mm. 3, 18 RGP regression has been shown to be associated with an adverse clinical outcome, both in lesions without and with an adjacent VGP. 5 The presence of complete regression in the RGP of lesions with VGP was associated with poorer survival in a prognostic model published by Clark et al. 4 The extent of regression in thin melanomas has also been associated with poorer prognosis. 22, 25 The association of RGP regression with a brisk lymphocytic infiltrate and absent melanoma cells has been taken to reflect a host response directed against malignant cells. Paradoxically, the presence of brisk tumor-infiltrating lymphocytes (TIL) in the VGP is a favorable prognostic factor. Therefore, it is puzzling that RGP regression is associated with a worse clinical outcome, and the mechanisms underlying these phenomena have remained obscure.
Our earlier studies showed that lymphatic vessel density (LD) is significantly increased in melanomas compared with either commonly acquired or dysplastic nevi. 12 Furthermore, lymphatic invasion (LI) in primary melanomas is much more frequently observed when using dual immunohistochemical (IHC) markers for lymphatic vessels and for melanoma cells rather than routine histology. 28 Other groups have shown that lymphangiogenesis in melanoma is associated with an increased incidence of sentinel lymph node (SLN) metastases and shorter disease-free survival. 21 Barnhill and Levy 1 reported that areas of RGP regression had strikingly greater vascularity than areas without regression. However, their study did not address whether the increased vascularity was made up of lymphatic or blood vessels. In this study, we used a cohort of 321 patients with VGP primary melanomas who had 10 years or more of followup. Patients with invasive RGP without VGP were not included in the study because it has been reported that over 95% of these patients did not have recurrence of disease even after more than 10 years of follow-up, as described in the study of Clark et al. 4 We asked whether the prognostic value of RGP regression could be ascribed to increased LD and LI in areas of regression.
PATIENTS AND METHODS

Study Patients and Study Design
This study is a retrospective cohort study that included patients seen between 1972 and 1991 at the Pigmented Lesion Clinic of the University of Pennsylvania. Patients eligible for this study had VGP primary melanomas and no apparent metastasis at the time of definitive treatment. This study included 346 patients who had at least 10 years of follow-up and had paraffin blocks available for IHC staining. We excluded 25 cases in which stained tissue sections were technically poor (n = 21), had no residual VGP on the IHC-stained slides (n = 3), and 1 case in which no consensus could be reached by 2 pathologists. The study protocol was approved by the institutional review board of the University of Pennsylvania.
IHC Staining
The lymphatic endothelium was visualized with the brown chromogen, diaminobenzidine (DakoCytomation, Carpinteria, CA), and melanoma cells with Nova Red (Vector Laboratories, Burlingame, CA). The D2-40 antibody (mouse monoclonal, 1:25 dilution, Signet Laboratories, Dedham, MA) that specifically detects a fixation-resistant epitope on podoplanin was used to decorate the lymphatic endothelium. 13, 19 Melanoma cells were identified using the S-100 antibody (rabbit polyclonal, 1:50 dilution; DakoCytomation). IHC assays were carried out on 5-mm-thick, formalin-fixed, paraffin-embedded sections. 16 Heat-induced epitope retrieval was performed by boiling the slides in 1x ethylenediaminetetraacetic acid buffer (LabVision, Fremont, CA) for 20 minutes. The slides were incubated with the D2-40 and S-100 antibodies for 1 hour at room temperature. Staining was performed on a DakoCytomation Autostainer using the EnVision + horseradish peroxidase diaminobenzidine system (DakoCytomation) according to the manufacturer's recommendations. Normal mouse serum (1:1000 dilution) was substituted for the primary antibody in each case as a negative control.
Pathology Definitions
All the slides were originally reviewed for routine histologic attributes by 2 pathologists (D.E.D and Clark WH, Jr) without the knowledge of patients' outcomes as described earlier. 4 Attributes included tumor thickness; dermal mitotic rate, expressed in mitoses per square millimeter; VGP TIL, classified as present or absent; and regression, if present in the invasive or in situ RGP adjacent to the VGP; and ulceration. Subsequently, cut and prepared IHC-stained slides were reviewed independently by 2 dermatopathologists (Y.S.J. and X.X.) who were also blinded to the clinical outcome.
Complete and partial regression was defined as noted in the introduction (Figs. 1A, B, E, and F). LD was quantified by counting the number of lymphatic vessels in 1 mm 2 in "hot spots" within the areas of complete or partial regression. Hot spots were discrete areas with easily visible lymphatic vessels, which were positive for podoplanin staining ( Fig. 2A ). Agreement on LD between 2 reviewers was first established by the Altman-Bland approach, 2 and the average of LD was used in all the analyses.
We found that double staining for melanoma cells and lymphatic endothelial cells was optimal to identify LI. S-100 ( Fig. 1C ), Melan-A ( Fig. 1D ), or podoplanin alone was not sufficient to identify LI. LI was defined by S-100-positive cell(s) present in lymphatic vessel lumens within the area of regression (Figs. 2B, C). We also compared LD in regression with that in the normal dermis immediately adjacent to the regressed area and the "distant" histologically normal dermis (at least 1 mm away from any area of regression, RGP, or VGP).
Clinical Definitions
In this study patients were recruited from a cohort that predated the use of staging with sentinel node biopsies and followed for 10 to 35 years per protocol. The primary end point was "first metastasis" within 10 years of diagnosis in which metastasis was defined to be metastasis to regional nodes, disseminated disease, or, in the absence of information on the preceding metastases, melanoma-specific death (MSD). Time to first metastasis (TFM) was defined as the time from definitive surgery to the first metastasis, as defined above. Of 41 patients who received elective lymph node dissections (ELNDs), 16 (39%) patients had histologically positive nodes, and these patients were not used in the calculation of the TFM. Consequently, for those with an ELND, the TFM was observed if there was recurrence of disease in nonregional nodes, disseminated disease, or melanoma-related death. Patients were censored due to death unrelated to melanoma or if they were alive at the time of the last follow-up. The median follow-up for those alive at the last follow-up was 20.4 years (n = 215; range, 2.2 to 33.5 y). The median TFM was 2.02 years (n = 106 patients; range, 0.05 to 21.6 y).
Statistical Methods
Patient and tumor characteristics were compared between patients with and without areas of complete regression and between those with partial and no regression using Pearson w 2 statistics or the Fisher exact test. LD was compared between the areas of complete and partial regression, and between normal areas that were adjacent and distant from the tumor using t tests with the Satterthwaite modification for unequal variances. The primary analysis was to examine the association of TFM and regression with the areas of regression further classified to its extent (complete, partial, or none), density of lymphatic vessels (LD high or low), and the presence of LI (present or absent). The secondary analysis was focused on the time to melanoma-specific death (MSD). We determined an optimal cut-point for LD as that was associated with the most significant difference between the 2 survival curves defined by the range of potential cutpoints. Kaplan-Meier curves were estimated for TFM, and the log-rank test was used to identify significant differences between curves defined by the variables. Cox proportional hazards regression models were used to obtain unadjusted and adjusted hazard ratios (HRs) (with associated 95% confidence intervals) and to investigate how a more specific classification of the area of regression (extent, LD and LI, and the interaction of LD and LI) would mediate the association. A P value for a pairwise comparison of 2 survival curves ( Fig. 3 ) was considered significant if it was r0.01 based on the Bonferroni adjustment for multiple hypothesis testing. These analyses were carried out using SAS (version 9.1.). P values were based on 2-sided tests.
RESULTS
Patient and Lesion Characteristics
The characteristics of the patients and their tumors are presented in Table 1 . In this study, 75 lesions (23%) had complete regression and 41 lesions (13%) had partial regression. There were no significant differences in these characteristics between those with melanomas that had areas of partial regression and those that had no area of regression. However, there were significant differences in tumor-related characteristics among those with melanomas that had areas of complete regression and those whose lesions had no complete regression. Ulceration was significantly more likely in lesions with complete regression (29%) compared with those with partial regression (9%) or no regression (19%) (P = 0.029). In addition, VGP TIL were more often observed in melanomas with complete RGP regression (85%) compared with those with either partial regression (68%) or no regression (65%) (P = 0.005).
LD Was Increased in the Area of Regression in Melanoma
Most of the vascular channels within the areas of RGP regression were lymphatic, staining strongly with podoplanin ( Fig. 2A) . LD significantly decreased in a stepwise manner from the 75 areas of complete regression (mean±SD, 23.7±12.3/mm 2 ) to the 41 areas of partial regression (15.5±7.1/mm 2 ), to the 155 areas of the (Table 2) . Patients with melanomas with areas of complete regression were classified into 2 groups: 44 patients with low LD (r24.5/mm 2 ) and 31 patietns with high LD (>24.5/mm 2 ). This was done using the optimal cut-point for LD equal to 24.5, a value that was close to the median value of LD, which was 22.5/mm 2 .
LI Was Observed in the Area of Regression in Melanoma
Among patients with melanomas that had either an area of complete or partial regression (n = 116), 21.6% of patients were observed to have LI in the area of regression (Figs. 2B, C) . We note that LI was significantly more likely to be observed in the areas of complete regression (24%) than it was in the areas of partial regression (12%) (P<0.001).
High LD and LI in the Area of Complete Regression Were Associated With Poor Prognosis
Patients with lesions exhibiting complete regression had shorter TFM (HR = 1.63, P = 0.021) and shorter time to MSD (HR = 1,63, P = 0.036) than those with lesions having partial or no regression (Table 3 , model 1). Patients with lesions having high LD in areas of complete regression had shorter TFM (HR = 2.8, Pr0.001) and shorter time to MSD (HR = 2.6, P = 0.001) compared with patients whose lesions did not have areas of complete regression (Table 3, model 2). Interestingly, patients with low LD in RGP areas of complete regression had similar clinical outcomes compared with patients whose melanomas did not have complete regression (HR = 1.0, P = 0.882 for TFM and HR = 1.1, P = 0.720 for MSD) (Table 3, model 2). Patients whose lesions had LI in the area of complete regression had shorter TFM (HR = 2.9, Pr0.001) and shorter time to MSD (HR = 2.4, P = 0.016) than those whose lesions had areas of complete regression without LI (HR = 1.3, P = 0.295 for TFM and HR = 1.4, P = 0.204 for MSD), compared with those without complete regression (Table 3 , model 3). Figure 3 presents the 4 survival curves for patients with lesions with an area of complete regression subdivided into groups defined by LD (high and low), LI (present and absent), and the survival curve for those whose lesions were without an area of complete regression. On the basis of the HRs from the Cox model (Table 3 , model 2), patients whose lesions had areas of complete regression with LI (and either high or low LD) or with no LI with high LD had shorter TFM (HR = 2.5, 3.8, and 2.5, respectively) than those with no LI and low LD (unadjusted HR = 0.7, P = 0.291) or those without areas of complete regression.
DISCUSSION
This study shows for the first time that regression in the RGP adjacent to the VGP of primary melanomas is associated with lymphangiogenesis and LI. Furthermore, high LD or the presence of LI in the area of RGP regression may be used to stratify patients having areas of complete regression into high-risk or low-risk groups. In addition, partial RGP regression does not seem to be associated with worse prognosis.
We and other researchers have shown that RGP regression is an adverse prognostic factor. 4, 10, 22, 25 However, more recent studies are inconsistent on the association of regression with metastasis to the SLNs. 11, 15, 20 Olah et al 20 reported a significant association of SLN metastasis and regression, whereas Fontaine et al 11 reported no association. Kaur et al 15 used a histopathologic staging system for regression and concluded that regression is associated with a favorable prognosis in thin melanomas. The variable results in these studies may be explained by the different criteria used to define regression and whether partial regression was included in the analyses. In this study, we compared complete and partial regression as defined by Clark et al 4 adverse prognostic factor for both TFM and MSD, whereas partial regression is not. It is unclear why partial regression was not associated with adverse prognosis. We postulate that partial regression is an intermediate state and it may evolve to complete regression with time. The extra time to reach complete regression may allow further lymphangiogenesis and LI within the lesion.
and found that complete regression is an
A strength of the study is that time to metastasis was not confounded by sentinel node biopsy, which finds metastases that are not clinically evident. However, in the era from which these cases are derived, some patients received ELNDs. The results of the ELND were not used in the calculation of the TFM. Consequently, for those with an ELND, the TFM was observed if there was recurrence of disease in nonregional nodes, disseminated disease, or melanoma-related death. We computed the HR for those with and without ELND. There was no significant difference in the hazard of disease recurrence between the 2 groups.
One of the key histologic features in regression is an increased number of vascular channels. We found that most of these microvessels were lymphatic, and that LD in a regressed area was significantly higher than immediate adjacent normal or distant normal dermis, likely indicating active lymphangiogenesis in the areas of regression. There are a number of studies that have showed that increased LD in melanoma is associated with poor prognosis. 6, 7, 17, 24, 27 One study showed that LD in primary melanomas with VGP was a significant independent prognostic indicator for the presence of metastases in SLNs, having a stronger statistical association than tumor thickness. 7 High peritumoral or intratumoral LD was associated with SLN metastasis and shorter survival. 17 Our results echo these findings and showed that high LD in the regressed area is also associated with poorer prognosis.
RGP regression is associated with dense lymphohistiocytic infiltrates. Although T cells do not express vascular endothelial growth factor (VEGF)-C, it has been shown that tumor-infiltrating macrophages secrete VEGF-C and VEGF-D, 7,17,23 key growth factors regulating lymphangiogenesis. 14 The number of lymphatic vessels has been shown to directly correlate with the intensity of the inflammatory infiltrate in and around the tumor. 6, 17, 26 Therefore, it is plausible that the inflammatory cells in the area of regression may play a significant role in lymphangiogenesis.
It is interesting to note that melanoma cells can be seen within lymphatic vessels in areas of regression. We have shown earlier that LI was common (33%) in primary melanomas with VGP using dual IHC staining rather than routine morphology (4.7%). 28 Doeden et al 8 reported that LI was associated with SLN metastasis. In this study, we found that LI was detected more frequently in areas of complete regression (23.5%) than in areas of partial regression (14.6%). Lesions having areas of complete regression that included LI, with or without high LD, had a poorer prognosis than those without an area of complete regression (HR = 2.5 and 3.8, P = 0.019 and 0.004, respectively).
These results suggest that the adverse prognostic effect of RGP regression is mediated through increased LD and/or LI in the area of complete regression, whereas partial regression does not seem to be associated with worse prognosis. *Multivariate models included the indicators for lymphatic invasion, extent of lymphatic vessel density, and their interaction as indicated in the description of the models above, and the 2010 American Joint Commission on Cancer Stage indicators for stages IA and IB with stage II as the reference group.
